ShedRx vs. Yucca Health: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, Yucca Health is the cheaper program at $258 a month all-in versus ShedRx's $289 — a gap of $31 a month, $372 a year, at the 10 mg maintenance basis. ShedRx: $289 a month all-in at the 10 mg maintenance basis, dose-scaled from a $199 entry, no membership fee. Yucca Health: $258 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $225/mo (6-month plan). Prepaid terms reorder things: Yucca Health at $225/mo (6-month plan) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, Yucca Health wins at $146 versus $249 all-in — $103/mo apart. ShedRx: Semaglutide runs $249 a month all-in at the standing rate ($175 on intro/plan terms). Yucca Health: Semaglutide runs $146 a month all-in.

Transparency

ShedRx: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. Yucca Health: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

ShedRx: none month-to-month; 72-hour notice before the next billing cycle. Yucca Health: 6-month term; 6-month term applies.

The gap, compounded over time

Price gaps in this market are best read on a calendar. ShedRx's premium over Yucca Health compounds to: one month, $31; six months, $186; a year, $372; two years of maintenance, $744. Only Yucca Health publishes a prepaid tier ($225/mo effective), which undercuts even ShedRx's standing $289 by $768/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

The two-year totals put the monthly gap in its true scale: ShedRx bills $6,936 and Yucca Health $6,192, a spread of $744 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, Yucca Health's $225 effective would total $5,400 — $792 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: ShedRx scales $199 → ~$289 by 10 mg (titration lands between $796 and $1,156); Yucca Health holds $258 on every rung (four-month titration: exactly $1,032). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $199 at ShedRx versus $258 at Yucca Health for the 2.5 mg rung — an early edge that reverses once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,096/year at Yucca Health against $3,468 at the other: $372 of annual daylight for the same molecule and dose. The committed prepayer does best at Yucca Health: $225/month effective, $2,700/year, funds up front, refund terms first.

The semaglutide board

Yucca Health takes the semaglutide board too at $146 versus $249 all-in — a $103/month, $1,236/year spread. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. ShedRx's ranked figure is $289, with no membership to add; Yucca Health's ranked figure is $258, with no membership to add. 2 · Maintenance basis. ShedRx scales from $199 to $289, and the 10 mg figure is the one ranked; Yucca Health is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. ShedRx: standing $289, no prepaid tier; Yucca Health: standing $258, prepaid $225 effective (6-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. ShedRx: source-verified, read 2026-08-05; Yucca Health: source-verified, read 2026-08-05. 5 · Pharmacy weighed. ShedRx names no pharmacy; Yucca Health names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

ShedRx: no membership — the medication figure is the billed figure; 72-hour notice before the next billing cycle; commitment: none month-to-month. Yucca Health: no membership — the medication figure is the billed figure; prepaid 6-month plan at $225/mo effective; 6-month term applies. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

ShedRx carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Yucca Health carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: ShedRx: shipping included; consultation included; async visit model. Yucca Health: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick ShedRx if its published terms happen to fit your state, format, or timing. Pick Yucca Health if the $31/month tirzepatide saving is the point; the semaglutide line is cheaper here; you want a price that survives titration; you'll prepay for the $225 effective rate. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Widen the frame one step and the strongest adjacent options are IVIM Health at $278 (dose-scaled, $75 membership included); Mochi Health at $278 (flat, $79 membership included, named pharmacy); Found at $289 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $2,292/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, Yucca Health is the cheaper tirzepatide program by $31/mo and it doesn't trade that price for opacity. Both records, with dates and sources, live in the pricing database.